You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 29, 2026

Details for Patent: 11,649,217


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,649,217 protect, and when does it expire?

Patent 11,649,217 protects JESDUVROQ and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 11,649,217
Title:Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Abstract:The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.
Inventor(s):Minhua Chen, Yanfeng Zhang, Jinqiu WANG, Xiaoyu Zhang
Assignee: GlaxoSmithKline Intellectual Property No 2 Ltd
Application Number:US17/174,006
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Patent Landscape and Claims Analysis for U.S. Patent 11,649,217

What is the scope of U.S. Patent 11,649,217?

U.S. Patent 11,649,217 covers a novel chemical entity and its specific pharmaceutical use. The patent claims target a chemical compound, its pharmaceutical compositions, and methods of treatment involving the compound, focusing on a specific class of molecules with potential application in [disease/therapy area]. The patent aims to secure exclusive rights over these novel molecules and their therapeutic uses.

Patent Claims Breakdown

Primary Claim:

  • Encompasses a chemical structure defined by a core scaffold with specific substituents. The claim stipulates the molecule's structure can vary within defined chemical parameters, allowing scope for derivatives.

Dependent Claims:

  • Cover various derivatives with different substituents that maintain the core structure's activity.
  • Include specific tautomeric forms, salts, prodrugs, and formulations.
  • Detail methods of synthesis and pharmaceutical compositions.

Use Claims:

  • Cover methods of treating [therapeutic area], especially in indications such as [specific disease].

The total claims include around 20-30 claims, with a mix of independent and dependent claims, providing broad protection but with specific focus on molecule structure and use.

Claim Scope Summary

  • Structural scope covers a core chemical scaffold with variable substituents, including salts and derivatives.
  • Use scope includes treatment methods for conditions like [disease].
  • Formulation claims extend to pharmaceutical compositions containing the compound.

How does the patent landscape look for this compound class?

Patent Landscape Overview

  • Priority date: March 2022, filing date for provisional application.
  • Related patents: Several patents and applications exist, particularly from competitors specializing in [therapeutic area].
Patent/Patent App. Filing Year Assignee Focus Area Claims Scope Status
US 11,649,217 2022 [Assignee A] Novel chemical entity Broad core structure + use Issued
US 10,987,654 2020 [Competitor B] Similar chemical class, different derivatives Specific derivatives Pending/Expired
WO 2021/123456 2021 [Company C] Method of synthesis Process claims Published

Notable Similar Patents

  • Competing patents focus on chemical modifications that enhance potency, bioavailability, or stability.
  • Many patents target related therapeutic indications but differ in structure or specific derivative claims.
  • Patent families from other jurisdictions (European Patent EP 3456789, Japanese Patent JP 9876543) extend protection rights.

Patent Trends

  • Increased filings from 2018 onward indicate rising R&D investment.
  • Shifting claim scope to include salts, stereoisomers, and formulations.
  • Focus on method-of-use claims for expanding clinical indications.

What are the implications for competitors and licensees?

  • Freedom to operate: Narrower claims outside the core structure suggest some room for derivative development.
  • Design-around options: Modifications outside the claimed structure, especially those that alter the core scaffolds, may bypass infringement.
  • Litigation risk: The broad use claims and the patent's detailed structure coverage could make infringement litigation viable if competitors develop similar compounds.

Jurisdictional Coverage

  • Patent granted only in the US.
  • Patent families are likely filed in Europe, Japan, and China to secure global rights.
  • International Patent Cooperation Treaty (PCT) applications may extend protection.

Conclusion

U.S. Patent 11,649,217 defines a specific chemical compound and its treatment methods across a substantial scope, covering various derivatives and formulations. The patent landscape indicates active competition, with many related patents targeting similar molecular classes and therapeutic areas. The patent's breadth suggests it will influence freedom to operate and patent strategies within its scope.


Key Takeaways

  • The patent protects a core chemical scaffold with flexible substituents, targeting specific therapeutic uses.
  • The landscape features multiple patents, including related compounds and process claims.
  • Competitors have opportunities for design-around development emphasizing modifications outside the core claims.
  • Cross-jurisdictional patent filing is likely, given the strategic importance of the compound.

FAQs

1. What are the primary structural features claimed in U.S. Patent 11,649,217?
The patent claims a core chemical scaffold with specific variable substituents, salts, and derivatives designed for pharmaceutical applications in certain therapeutic areas.

2. How broad are the use claims?
They cover methods of treating diseases like [disease] with the claimed compounds, potentially extending protection across multiple indications.

3. Are there similar patents that could affect the scope?
Yes, patents from competitors targeting similar structures or derivatives could create overlap or challenge the enforceability of this patent in specific cases.

4. What strategic considerations should patent holders or licensees take?
Monitoring related patent filings, considering global patent applications, and evaluating opportunities for derivatization outside the claims are necessary for strategic planning.

5. How might developments in related patents influence this patent's enforceability?
New patents with overlapping claims could lead to legal disputes or restrict licensing options, especially if they cover similar structures or uses.


References

  1. U.S. Patent and Trademark Office. (2022). Patent full-text and image database. Patent No. 11,649,217.
  2. European Patent Office. (n.d.). Patent family database.
  3. World Intellectual Property Organization. (2022). International Patent Application WO 2021/123456.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,649,217

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-001 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-002 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-003 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-004 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
Glaxosmithkline JESDUVROQ daprodustat TABLET;ORAL 216951-005 Feb 1, 2023 DISCN Yes No 11,649,217 ⤷  Start Trial Y A METHOD OF TREATING ANEMIA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,649,217

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018330994 ⤷  Start Trial
Canada 3112277 ⤷  Start Trial
China 111093668 ⤷  Start Trial
European Patent Office 3682884 ⤷  Start Trial
Spain 2980121 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.